GW Pharma
Trial of Jazz’ cannabis drug in glioblastoma will start next year
Phil Taylor
cannabinoid, glioblastoma, GW Pharma, Jazz Pharmaceuticals, Oncology, Sativex
0 Comment
Jazz lifted by third EU approval for GW Pharma’s Epidyolex
Phil Taylor
cannabis, Epidyolex, epilepsy, EU, GW Pharma, Jazz Pharmaceuticals, rare disease
0 Comment
News/ News/ Sales and Marketing
Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma
Phil Taylor
cannabis, Epidiolex, GW Pharma, Jazz Pharmaceuticals, M&A
0 Comment
AZ picks up $350m after selling hypertension drugs
Richard Staines
AstraZeneca, Bayer, cancer, cardiology, GW Pharma, hypertension, multiple sclerosis
0 Comment
GW Pharma tops list of UK R&D spenders
Richard Staines
AstraZeneca, Circassis, GlaxoSmithKline, GW Pharma, R&D
0 Comment
GW confident epilepsy drug will get NHS funding despite NICE rejection
Richard Staines
Epidyolex, epilepsy, GW Pharma, market access
0 Comment
Review finds medical benefits of cannabis-based drugs
Piotr Wnuk
cannabinoid, cannabis, Epidolex, GW Pharma
0 Comment